176 related articles for article (PubMed ID: 35320951)
1. Vimentin Protein In Situ Expression Predicts Less Tumor Metastasis and Overall Better Survival of Endometrial Carcinoma.
Zhang X; Cao G; Diao X; Bai W; Zhang Y; Wang S
Dis Markers; 2022; 2022():5240046. PubMed ID: 35320951
[TBL] [Abstract][Full Text] [Related]
2. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
Zhang Q; Xia T; Qi C; Du J; Ye C
BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
[TBL] [Abstract][Full Text] [Related]
3. Rictor is an independent prognostic factor for endometrial carcinoma.
Wen SY; Li CH; Zhang YL; Bian YH; Ma L; Ge QL; Teng YC; Zhang ZG
Int J Clin Exp Pathol; 2014; 7(5):2068-78. PubMed ID: 24966915
[TBL] [Abstract][Full Text] [Related]
4. Prediction of lymphovascular space invasion in endometrial cancer using the 55-gene signature selected by DNA microarray analysis.
Watanabe T; Honma R; Kojima M; Nomura S; Furukawa S; Soeda S; Watanabe S; Fujimori K
PLoS One; 2019; 14(9):e0223178. PubMed ID: 31557240
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis.
Shang P; Meng F; Liu Y; Chen X
Tumour Biol; 2015 Jun; 36(6):4479-85. PubMed ID: 25934333
[TBL] [Abstract][Full Text] [Related]
6. Lymph-vascular space invasion and number of positive para-aortic node groups predict survival in node-positive patients with endometrial cancer.
Watari H; Todo Y; Takeda M; Ebina Y; Yamamoto R; Sakuragi N
Gynecol Oncol; 2005 Mar; 96(3):651-7. PubMed ID: 15721407
[TBL] [Abstract][Full Text] [Related]
7. NCAPH is upregulated in endometrial cancer and associated with poor clinicopathologic characteristics.
Qiu X; Gao Z; Shao J; Li H
Ann Hum Genet; 2020 Nov; 84(6):437-446. PubMed ID: 32628282
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a nine-gene prognostic model for predicting overall survival of patients with endometrial carcinoma.
Ying J; Wang Q; Xu T; Lyu J
Cancer Med; 2018 Jun; 7(6):2601-2611. PubMed ID: 29665298
[TBL] [Abstract][Full Text] [Related]
9. Silencing of UCA1, a poor prognostic factor, inhibited the migration of endometrial cancer cell.
Lu L; Shen Y; Tseng KF; Liu W; Duan H; Meng W
Cancer Biomark; 2016 Jun; 17(2):171-7. PubMed ID: 27540975
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of 16α-
Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
[TBL] [Abstract][Full Text] [Related]
11. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival.
Mauland KK; Wik E; Hoivik EA; Kusonmano K; Halle MK; Berg A; Haugland HK; Øyan AM; Kalland KH; Stefansson IM; Akslen LA; Krakstad C; Trovik J; Werner HM; Salvesen HB
Oncotarget; 2017 Feb; 8(6):9696-9707. PubMed ID: 28039471
[TBL] [Abstract][Full Text] [Related]
12. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
13. CKMT1A is a novel potential prognostic biomarker in patients with endometrial cancer.
Wang Y; Zhao S; Qin Q; Gao X; Zhang X; Zhang M; Jiang Y; Ji X; Zhu H; Zhao X; Li H
PLoS One; 2022; 17(1):e0262000. PubMed ID: 35077462
[TBL] [Abstract][Full Text] [Related]
14. Expression of bone morphogenetic protein 10 in cases with endometrial carcinoma and its clinical significance.
Hu Y; Yu L; Xia F; Liang F; Cheng C; Huang Y; Xiao L
Clin Transl Oncol; 2021 Aug; 23(8):1711-1716. PubMed ID: 33635467
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Bildrici K; Tel N; Ozalp SS; Yalcin OT; Yilmaz V
Eur J Gynaecol Oncol; 2002; 23(6):540-4. PubMed ID: 12556100
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
17. Lymphadenectomy in women with endometrial cancer: aspiration and reality from a radiation oncologist's point of view.
Foerster R; Kluck R; Arians N; Rieken S; Rief H; Adeberg S; Bostel T; Schlampp I; Debus J; Lindel K
Radiat Oncol; 2015 Jul; 10():147. PubMed ID: 26179059
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of MMSET in endometrial cancer: a clinicopathologic study.
Xiao M; Yang S; Chen J; Ning X; Guo L; Huang K; Sui L
J Surg Oncol; 2013 Mar; 107(4):428-32. PubMed ID: 22886632
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of LncRNA FER1L4 in endometrial carcinoma is associated with favorable survival outcome.
Kong Y; Ren Z
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8113-8118. PubMed ID: 30556848
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
